Company will resume trading under its existing symbols “BTMD” and “BTMDW” IRVING, Texas --(BUSINESS WIRE)--Aug. 25, 2022-- biote Corp. (“Biote” or the “Company”), a high growth, differentiated medical practice-building business within the hormone optimization space, today announced that The Nasdaq

IRVING, Texas --(BUSINESS WIRE)--Aug. 24, 2022-- biote Corp. (“Biote” or the “Company”), a high growth, differentiated medical practice-building business within the hormone optimization space, today announced that it has appointed Samar Kamdar as its Chief Financial Officer. Mr.

IRVING, Texas --(BUSINESS WIRE)--Aug. 15, 2022-- Biote today issued a correction to operating loss and net income for the three and six month periods ended June 30, 2022 in the press release titled “Biote Reports Second Quarter 2022 Financial Results,” issued on August 9, 2022 .

Company generates accelerated Revenue, net income and adjusted EBITDA growth, and raises 2022 adjusted EBITDA guidance * Revised Dial -in Information for the Conference Call* IRVING, Texas --(BUSINESS WIRE)--Aug. 9, 2022-- Biote , a high growth, differentiated medical practice-building business

IRVING, Texas --(BUSINESS WIRE)--Jul. 20, 2022-- biote Corp. (“Biote” or the “Company”) (Nasdaq: BTMD), a high growth, medical practice-building business within the hormone optimization space, will report its financial results for the second quarter ended June 30, 2022 , after market close on

  Innovative physician leader brings over 20 years of experience to Biote’s executive team IRVING, Texas --(BUSINESS WIRE)--Jun. 16, 2022-- biote Corp. (“Biote” or the “Company”) (Nasdaq: BTMD), a high growth, medical practice-building business within the hormone optimization space, today announced

IRVING, Texas --(BUSINESS WIRE)--Jun. 6, 2022-- biote Corp. (“Biote” or the “Company”) (Nasdaq: BTMD), a high growth, differentiated medical practice-building business within the hormone optimization space, today announces that Terry Weber , Biote’s Chief Executive Officer, is scheduled to present

Survey reveals 4 out of every 10 women reported that menopause symptoms have interfered with their work performance or productivity at least on a weekly basis IRVING, Texas --(BUSINESS WIRE)--Jun. 6, 2022-- Biote , a leading hormone optimization company, today publicly released findings of a 2022

Business combination with Haymaker Acquisition Corp. III complete biote Corp.’s common stock will trade on the Nasdaq Stock Exchange under ticker symbol “BTMD” IRVING, Texas --(BUSINESS WIRE)--May 26, 2022-- biote Corp., (Nasdaq: BTMD) (“Biote” or the “Company”), a high growth, differentiated

NEW YORK, May 24, 2022 (GLOBE NEWSWIRE)  — Haymaker Acquisition Corp. III (Nasdaq: HYAC) (“Haymaker” or the “Company”), a publicly traded special purpose acquisition company, today announced that its stockholders voted to approve the previously announced business combination (the “Business